Three insights:
1. The Hive implant’s soft titanium provides a lower modulus of elasticity than PEEK, developed to decrease the risk of collapse.
2. Regarding in-growth and on-growth, Hive’s interbodies allow for bone to spread laterally through porous walls. Its surface treatment provides a rough exterior and an oxide layer, which both support osteogenesis.
3. Radiographic imaging results from its lattice core and the lack of solid titanium features.
“Reaching 1,500 soft titanium implantations within two years of our first 510(k) clearance is a testament to our team’s consistent effort and focus,” said Luke Diehl, Co-Founder and CEO of HD LifeSciences. “Hive interbodies have proven to be durable, safe and effective.”
More articles on devices:
Zavation receives FDA approval for new spinal fusion device — 3 insights
Indiana device company receives FDA clearance for elbow system — 3 insights
Smith & Nephew acquires orthopedic joint reconstruction business — 4 insights
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
